Symptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in symptomatic catheter‐related thrombosis (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Symptomatic catheter‐related thrombosis measured as asymptomatic catheter‐related thrombosis (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic catheter‐related thrombosis measured as asymptomatic… compared with no VKA (very low certainty).
1 finding from 1 review
Major bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in major bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Minor bleeding · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in minor bleeding (up to 3 months) compared with no VKA (low certainty).
1 finding from 1 review
Antibiotic versus heparin only lock/flush solution: catheter‐related infections · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in catheter‐related infection (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Premature CVC removal (3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Vitamin K antagonist (VKA) showed no clear difference in premature CVC removal (3 months) compared with no VKA (low certainty).
1 finding from 1 review
Outcomes ( · people with cancer with thrombosis prophylaxis and central venous catheters
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vitamin A deficiency · general population of all age groups (including pregnant women) from any country, over two years of age
Rice fortified with iron alone or in combination with other… showed no clear difference in vitamin A deficiency (as defined by the study authors) compared with unfortified rice (no micronutrients added) (low certainty).
1 finding from 1 review
Intervention not reported
Vitamin A deficiency disorders · children and adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function · cognitively healthy people in mid and late life
6 findings from 1 review
Show 3 more findings
Intervention not reported
Vitamin A deficiency: retinol < 0.7 μmol/L · infants 1 to 6 months of age
The intervention showed no clear difference in vitamin A deficiency: retinol < 0.7 μmol/L (moderate certainty).
1 finding from 1 review
Incidence: lung cancer · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
Vitamins A, C, E + selenium + zinc showed no clear difference in incidence: lung cancer compared with placebo (high certainty).
1 finding from 1 review
Mortality: lung cancer · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence: all cancers · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
Vitamins A, C, E + selenium + zinc showed no clear difference in incidence: all cancers compared with placebo (high certainty).
1 finding from 1 review
Mortality: all cancers · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality: all causes · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
Vitamins A, C, E + selenium + zinc showed no clear difference in mortality: all causes compared with placebo (high certainty).
1 finding from 1 review
Clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline ESRS1 · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) may leads to higher clinical efficacy ‐ improvement (> 40%) in ESRS scores from baseline… compared with placebo (low certainty).
1 finding from 1 review
Global: Other adverse effects than tardive dyskinesia Self‐report by participants · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in global: Other adverse effects than tardive dyskinesia Self‐report by… compared with placebo (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms · patients with antipsychotic‐induced tardive dyskinesia
Pyridoxal 5 phosphate (vitamin B6) showed no clear difference in tardive dyskinesia: Deterioration in tardive dyskinesia symptoms ESRS1 compared with placebo (low certainty).
1 finding from 1 review